PreDiXome Bio is developing disease-state sensing technologies designed to identify integrated biological changes associated with cancer before conventional detection becomes possible.
“We believe cancer creates measurable biological state transitions before conventional detection, and we are building the tools to interpret them.”
Biological changes associated with cancer emerge before tumors become clinically detectable. Current diagnostic approaches primarily identify disease after measurable burden has developed. PreDiXome is investigating whether these earlier biological state transitions can be identified and interpreted.
Cancer creates measurable biological state transitions before conventional detection.
These transitions may reflect coordinated changes across cellular signaling, redox biology, metabolic function, and extracellular vesicle communication.
The Signara platform is being developed to identify and interpret these integrated disease-state signatures.
Disease emergence is not defined by a single biomarker. It is reflected through coordinated biological changes across cellular, metabolic, and signaling networks.
Structural and electrical changes associated with cellular state disruption.
Electron transfer imbalance and oxidative stress signatures.
Energetic instability and altered system behavior.
These processes converge into a measurable disease-state signature.
Cancer-associated biology emerges through interconnected system-level changes. PreDiXome is developing approaches designed to investigate integrated biological patterns rather than relying on single analytes alone.
PreDiXome is not measuring fragmented biomarkers.
It is investigating integrated functional disease states.
The Signara platform is designed to integrate biological signal capture, advanced sensing technologies, and computational interpretation into a unified disease-state analysis framework.
Capturing integrated biological state information reflected in extracellular vesicles.
A proprietary sensing architecture designed to detect coordinated electrochemical and biological state changes associated with disease emergence.
Transforming multidimensional biological signals into predictive disease-state intelligence.
Ovarian cancer serves as the initial application of the Signara platform. The underlying architecture is designed to support expansion across multiple cancers through integrated disease-state analysis.
Deep expertise in ovarian cancer biology and early disease emergence.
Apply and validate the platform across multiple high-impact cancer types.
Converging data and signal intelligence into a single, scalable MCED platform.
Establishing foundational biological datasets required to characterize disease-state biosignatures associated with ovarian cancer.
Physician-scientist focused on translating biological insight into clinically meaningful disease-state sensing technologies.
Advisor profiles and institutional affiliations to be confirmed and finalized for public release.
Funding foundational validation studies, biosensing development, translational research activities, and platform maturation.
We believe cancer creates measurable biological state transitions before conventional detection, and that understanding these transitions may enable a new generation of predictive oncology.
PreDiXome Bio is advancing a new approach to disease-state sensing — beginning with ovarian cancer and building toward a broader future of predictive oncology.